High impactLayoffs

BMS Ends Cellares Partnership Over Production Failures, Triggering ~100 Layoffs

NewsData.io · United States · Aug 26, 2026

Bristol Myers Squibb has terminated its $380 million capacity agreement with cell therapy manufacturer Cellares after determining the company's Cell Shuttle system could not meet requirements for commercial production of CAR-T therapy Breyanzi. Cellares will lay off approximately 100 employees on October 20, per a California WARN Act filing, affecting roles across engineering, marketing, recruitment, and software. The cuts come just 10 months after Cellares raised $257 million to scale toward commercial production. The layoffs signal continued volatility in the CDMO/cell therapy manufacturing sector, with ripple effects for specialized biotech talent demand.

Get the weekly brief by email

What changed in staffing last week, every Monday morning. Free. Unsubscribe anytime.

Bristol Myers SquibbCellaresOxford BioMedicabiotechcell therapyCDMOlife sciencesCAR-T

Related stories